Live News EQUITY FLASH L impact Oct 26, 2026, 11:10 AM UTC Can-Fite Says Namodenoson Meets Phase IIa Trial Safety Endpoint Can-Fite said namodenoson met the safety endpoint in a Phase IIa pancreatic cancer trial. SquawkNews Desk